OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Issue Information	521
	285
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	277
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	164
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	164
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	163
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	139
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	135
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	123
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	111
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	104
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	97
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	95
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	77
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	76
Are veterans at increased risk of myeloproliferative neoplasms?	73
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	73
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	69
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	69
Acute thrombocytopenia suggesting thrombotic microangiopathy	68
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	67
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	66
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	64
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	63
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	61

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	61
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	60
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	59
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	57
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	57
Clonal Hematopoiesis and Thrombosis	56
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	54
The latest insights into rare blood disorders: Diagnosis and treatment strategies	53
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	52
Molecular and clinicopathologic characterization of pediatric histiocytoses	52
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	52
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	50
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	50
Teclistamab in patients with multiple myeloma and impaired renal function	49
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	48
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	47
Table of Contents	46
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	46
Mini‐consolidations or intermediate‐dose cytarabine for the post‐remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries	45
	44